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ABSTRACT 
Cancer-associated fibroblasts (CAF) are orchestrators of the pancreatic ductal 
adenocarcinoma (PDAC) microenvironment. Stromal heterogeneity may explain differential 
pathophysiological roles of the stroma (pro- vs. anti-tumoral) in PDAC. We hypothesized that 
multiple CAF functional subtypes exist in PDAC, that contribute to stromal heterogeneity 
through interactions with cancer cells. Using molecular and functional analysis of patient-
derived CAF primary cultures, we demonstrated that human PDAC-derived CAFs display a 
high level of inter- and intra-tumour heterogeneity. We identified at least four subtypes of 
CAFs based on transcriptomic analysis, and propose a classification for human PDAC-derived 
CAFs (pCAFassigner). Multiple CAF subtypes co-existed in individual patient samples. The 
presence of these CAF subtypes in bulk tumours was confirmed using publicly available gene 
expression profiles, and immunostainings of CAF subtype markers. Each subtype displayed 
specific phenotypic features (matrix- and immune-related signatures, vimentin and α-
smooth muscle actin expression, proliferation rate), and was associated with an assessable 
prognostic impact. A prolonged exposure of non-tumoral pancreatic stellate cells to 
conditioned media from cancer cell lines (cancer education experiment) induced a CAF-like 
phenotype, including loss of capacity to revert to quiescence and an increase in the 
expression of genes related to CAF subtypes B and C. This classification demonstrates 
molecular and functional inter- and intra-tumoral heterogeneity of CAFs in human PDAC. 
Our subtypes overlap with those identified from single-cell analyses in other cancers, and 
pave the way for the development of therapies targeting specific CAF sub-populations in 
PDAC. 
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INTRODUCTION  
Pancreatic ductal adenocarcinoma (PDAC) is characterised by an abundant 
desmoplastic stroma, a complex structure composed of ECM proteins and various cell types 
including cancer-associated fibroblasts (CAF), immune cells, and endothelial cells [1]. CAFs 
are orchestrators of the PDAC microenvironment: they are responsible for excess ECM 
production and interact with both cancer cells and other stromal cells through a network of 
signalling pathways and mediators [2,3]. These interactions promote tumour growth, 
invasion, metastasis, and resistance to therapy [1,2]. A major source of CAFs in PDAC are 
pancreatic stellate cells (PSC), which are resident mesenchymal cells of the pancreas that, in 
their quiescent state, store vitamin A-containing lipid droplets [4,5]. Upon activation, PSCs 
lose this storage function, express α-smooth muscle actin (αSMA), and secrete ECM proteins 
and pro-tumoral factors [2,3,5]. The dynamics between non-tumoral PSCs and CAFs and 
their plasticity remain scarcely explored [6,7]. 
Recently, the role of the stroma and CAFs in PDAC has been questioned, by 
indications that CAFs may restrain rather than promote tumour growth [8,9]. Non-selective 
genetic disruption of CAFs, using αSMA-positive cell depletion [8] or pharmacological 
inhibition of the sonic hedgehog pathway [9,10], yielded aggressive tumours in mice and 
clinical trial failures, suggesting that some CAF sub-populations may be protective, and 
highlighting that caution should be exercised when targeting the stroma in PDAC. 
Inter-tumoral molecular heterogeneity of cancer cells in PDAC is well-established [11-
14]. Phenotypic stromal features (i.e. abundance of fibrosis and immune cell infiltration) also 
vary across tumours [15]. Because CAFs are at the crossroads of stromal compartments in 
PDAC, we hypothesised that the inter-tumour stromal heterogeneity may be related to 
patient-specific profiles of CAFs. Although there is increasing evidence for CAF heterogeneity 
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in various cancers [6,16], data about functional heterogeneity of CAFs in PDAC remain 
limited to murine experiments, mainly due to experimental challenges (i.e. difficulty of 
expanding primary cultures, small quantity of material, lack of subtype markers for cell 
sorting in PDAC) [7,17]. 
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MATERIALS AND METHODS 
Patient consent and ethical approval 
Ethics approval was obtained for the use of patient tumour samples. German contribution 
(human primary cultures): Ethics Committee of the Faculty of Medicine of the Technical 
University of Munich, number 1926/07; first approved 30 Oct 2007. Australian contribution 
(human primary cultures): institutional ethics approval number HREC11189/SESIAHS 00/088. 
French contribution (FFPE tumour samples): Beaujon biobank registration number BB-0033-
00078. UK contribution (pancreatic stellate cells): UK Human Tissue Bank; Trent MREC, 
05/MRE04/82. All participants gave informed consent before taking part. 
Primary CAFs 
Primary CAF cultures were isolated using the previously described outgrowth method (M. 
Apte’s and M. Erkan’s groups) [18]. All experiments for functional and molecular 
characterisation of CAFs were performed on a single passage for each CAF culture. All care 
was taken to minimise the effect of cell growth in artificial conditions by using early 
passages. 
RNA analysis 
The PanCancer Progression panel of genes was profiled using the nCounter® Max Analysis 
System (NanoString Technologies, Seattle, CA, USA). Data quality and normalization were 
performed using nSolver analysis software (NanoString Technologies) as per the 
manufacturer’s instructions and as described by us [19]. 
Subtype and signature identification 
Gene expression profiles were clustered using a consensus non-negative matrix factorization 
(NMF) approach using the R package NMF [20]. Prediction analysis of microarrays (PAM) was 
used to assign genes to specific subtypes using centroids, as described previously [21]. 
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Patient dataset and pCAFassigner subtypes 
The International Cancer Genome Consortium (ICGC) dataset from Bailey et al. [12], 
comprising 96 pancreatic samples (RNAseq), was used to assign pCAFassigner subtypes using 
PAM centroids generated from CAF primary cultures. The subtypes were assigned to the 
patient samples by correlating the PAM centroids and their corresponding gene expression 
(Pearson correlation) for each sample from the ICGC dataset. The subtypes were assigned 
based on highest correlation coefficient [22]. Potential second and third subtypes were 
assigned where the correlation coefficients were second and third highest and not negative. 
After subtype assignment, only PDAC samples (n = 70) were selected for the patient survival 
analysis. 
Cancer-education experiment 
MIAPaCa-2 and AsPC-1 cells were plated and split every three days at a fixed cell number. 
Before splitting, conditioned medium (CM) was taken and filtered using a 0.22-μm filter. In 
parallel, three flasks with a fixed number of PS1 cells were plated and split every six days: (1) 
in usual PS1 medium; (2) in a 1:1 mix of fresh PS1 medium and MIAPaCa-2-CM; and (3) in a 
1:1 mix of fresh PS1 medium and AsPC-1-CM, in order to obtain concurrent relevant 
educated PSCs with parental (control) PSCs with similar time lapsed in tissue-culture. Freshly 
harvested cancer cell CM was used to avoid alterations induced by freeze/thawing cycles. 
The same batch of FBS (Sigma-Aldrich, St Louis, MO, USA) was used over the whole 
experiment. After two months of culture, parental and educated PS1 cells were harvested 
for analyses. Cells were then cultured in standard PS1 medium for one month to test for 
reversibility. 
Statistical analyses 
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Experiments were performed in triplicates with immortalised cell lines. For primary cells, we 
obtained at least two primary cultures for each subtype, and analysed them to describe the 
biological properties of each pCAFassigner subtype. Unless otherwise stated, unpaired 
Student t-tests with Welch’s correction were used to compare two groups for continuous 
variables. Non-parametric one-way ANOVA using Kruskal-Wallis tests and Dunn’s multiple 
comparisons tests were performed to compare more than two groups. Results are expressed 
as mean ± SD. Survival curves were estimated with the Kaplan-Meier method and compared 
using the log-rank test. The level of significance for all tests was p < 0.05. Data were analysed 
using Prism software v.6.0. 
 
More details are provided in supplementary material, Supplementary Materials and 
Methods 
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RESULTS 
Transcriptomic analysis reveals inter-tumour heterogeneity of CAF primary cultures 
To test the hypothesis that PDAC-derived CAFs display inter-tumoral heterogeneity, 
we grew 16 primary CAF cultures from 16 different PDAC patients in the UK, Germany, and 
Australia (supplementary material, Table S1) and profiled them for 770 genes using the 
Nanostring nCounter Cancer Progression panel, which was appropriate for stromal gene 
expression, including ECM and epithelial-to-mesenchymal transition genes. The absence of 
contamination by cancer cells in the CAF cultures was verified by the lack of ubiquitous 
tumoral KRAS mutations (supplementary material, Figure S1A, Table S2). 
Initial unsupervised non-negative matrix factorization (NMF) clustering of highly 
variable 248 genes (SD > 0.8 across samples) from these CAF cultures defined four optimal 
CAF subtypes (pCAFassigner [pCAF] subtypes A-D; cophenetic coefficient > 0.99; Figure 1A, 
B; supplementary material, Figure S1B-D). The robustness of the four-cluster model was 
further validated using silhouette width and consensus clustering of samples after variable 
gene selection approach (supplementary material, Figures S1D, E, S2A-C). The four subtypes 
were characterised by distinct mRNA expression profiles (supplementary material, Figure 
Figure 2D) with the 15 most discriminating genes used for further validation (Figure 1C). 
Supervised clustering analysis using PAM-derived centroids (summary of gene expression 
per subtype) assigned the expression of the 248 genes to specific pCAF subtypes (Figure 1D). 
These results suggest that, amongst these primary human PDAC CAF cultures, at least four 
subtypes exist. 
Pathway enrichment analyses revealed that pCAF subtypes displayed partially 
overlapping pathways, with a significant enrichment (q-value, i.e. false discovery rate [FDR]-
adjusted p-value) of ECM-related gene sets across all subtypes, while subtype C expressed 
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immune-related pathways that were not found in other subtypes (Figure 1E). This finding 
suggested that pCAF subtypes are functionally distinct. 
Multiple CAF subtypes co-exist within each tumour sample 
Each CAF culture was assigned to one particular pCAF subtype based on the 
consensus clustering approach and predominant population according to the NMF’s highest 
probability score (Figure 2A). Our subtype clustering profile supported the hypothesis of 
multiple sub-populations (i.e. intra-tumour heterogeneity) within single patient-derived CAF 
cultures. Recently, Lambrechts et al. [16] described seven clusters of fibroblasts in normal 
lung and cancer microenvironment, using a single-cell RNAseq approach. We could 
demonstrate that PAM centroids from our pCAFassigner classification correlated with the 
Lambrechts classification (Figure 2B). Indeed, we observed that pCAFassigner subtypes 
showed overlap with multiple Lambrechts subtypes, supporting the notion of intra-tumoral 
heterogeneity. pCAF subtype A was primarily correlated with fibroblast 1 and 5 subtypes of 
Lambrechts et al., subtype B with fibroblast 1 and 4, subtype C with fibroblast 7 and subtype 
D with fibroblast 2 and 3. In addition, pCAFassigner subtype-specific genes showed specific 
clustering in Lambrechts et al. subtypes (supplementary material, Figure S3A). 
We next sought to explore the CAF intra-tumour heterogeneity within human PDAC 
samples. We screened antibodies for detection by IHC of the top 15 markers (Figure 1C) 
previously identified from the pCAFassigner. We selected markers that fulfilled the following 
criteria: (i) high mRNA expression in a specific subtype and low or no expression in other 
subtypes (Figures 1C, 2C, supplementary material, Figure S2D), (ii) strong or intermediate 
expression in fibroblasts by IHC, (iii) no or low expression by other stromal cells, unless part 
of an easily identifiable anatomical structure (e.g. artery, nerve), and (iv) no or low 
expression by cancer cells. POSTN (periostin), MYH11 (myosin-11), and PDPN (podoplanin) 
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were selected as pCAF subtype A-, B-, and C-related markers, respectively (Figure 2C-E, 
supplementary material, Figure S3B). No marker fulfilled all these criteria for pCAF subtype D 
(CXADR and MEOX were strongly expressed by tumour cells; PLS1 by endothelial cells).  
Immunohistochemistry (IHC) on serial sections from patient surgical samples showed 
the presence of POSTN, PDPN and MYH11 in spatially distinct areas of the tumour, 
suggesting expression of these markers by different CAF sub-populations (Figure 2D-E and 
supplementary material, Figure S3B). POSTN was present both at the invasive margin and in 
the centre of the tumours (juxta-tumoral stroma [<100 μm] and pan-stroma [23]), as 
previously reported [24], while MYH11 and PDPN were found only in the centre (juxta-
tumoral stroma and pan-stroma) (Figure 2E). In addition, we identified platelet-derived 
growth factor receptor α (PGDFRα) as a potential pan-subtype CAF marker, as described 
previously [25], whereas αSMA expression was not found in all CAFs [7] and was not specific 
to one particular subtype population (Figure 2D and supplementary material, Figure S3B). 
To rule out the hypothesis of co-expression of several markers by single cells, we 
performed an additional co-immunofluorescence experiment for POSTN, MYH11, and PDPN 
on three primary CAF cultures: PSC25 (subtype A), PSC48 (mixed, subtype A dominant > B) 
and PSC11 (subtype C) (Figure 2F and supplementary material, Figure S3C). In these primary 
cultures, there was predominant staining of the marker associated with the pCAFassigner 
subtype (POSTN in PSC25 and PSC48, PDPN in PSC11) over other markers. Furthermore, the 
other pCAFassigner markers were expressed focally in distinct cells (i.e. single marker 
expression, no overlap) at a much lower intensity or no expression at all. These findings 
were consistent with our transcriptomic results. Overall, these in vitro co-staining data again 
supported the co-existence of in vivo spatially distinct CAF populations within single 
tumours. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
The preponderance of pCAF subtype A amongst CAF primary cultures (n = 6/16, 
37.5%; Figure 2A) may be due to predominance of this subtype within patient samples 
(Figure 2D, E and supplementary material, Figure S3B) or alternatively a technical artefact 
(i.e. the outgrowth method preferentially favours subtype A). To explore this hypothesis, we 
validated externally the presence of the CAFs subtypes at the mRNA level (by applying our 
pCAFassigner signatures and PAM centroids to bulk RNAseq gene expression data available 
from the ICGC [12], n = 70) and at the protein level (by IHC in Beaujon cohort, n = 50) in situ 
in PDAC samples. Consistent with primary cultures, subtype A CAFs were the most 
frequently represented subtype in the ICGC dataset (proportion of samples with subtype A 
as first or second subtypes: 40%) and in the IHC cohort (proportion of samples with high 
POSTN [subtype A marker] expression: 54%), supporting both inter- and intra-tumoral 
heterogeneity of CAFs and subtype A predominance, and, moreover, confirming that ex vivo 
culture had a limited impact (supplementary material, Tables S3-S5). 
CAF subtypes have a prognostic impact 
We next considered the dominant pCAFassigner subtype in each patient sample 
within the ICGC cohort to explore the impact on survival (Figure 3A). We observed a 
significant difference in overall survival (OS) between the four pCAFassigner subtypes (p = 
0.02) (Figure 3A). Subtype D-dominant samples had the poorest prognosis (p = 0.03), with a 
median OS of 9.9 months, while patients with dominant subtype C had prolonged survival (p 
= 0.004), with a median OS of 50.4 months, and those with dominant subtype A or B had a 
poor/intermediate prognosis (median OS of 16.6 and 19.8 months, respectively) (Figure 3A 
and supplementary material, Table S3). 
We then assessed the prognostic impact of POSTN, MYH11, and PDPN levels by IHC in 
the Beaujon cohort. High POSTN expression (defined as moderate or strong staining in >50% 
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of stromal surface) was associated with significantly shorter OS (median: 29.8 vs. 46.2 
months, p = 0.005) (Figure 3B). In addition, combined POSTN, MYH11, and PDPN status 
defined three risk groups with poor (POSTN only / subtype A-like, median OS: 25.7 months), 
intermediate (MYH11 ± POSTN / subtype B-like, median OS: 30.9 months), and good (PDPN ± 
POSTN / subtype C-like, median OS: 49.6 months) prognosis (p = 0.01) (Figure 3C). 
Furthermore, we categorised our pCAFassigner subtypes from the ICGC data into 
Moffitt et al. activated vs. normal stromal subtypes [13] using their signature and NTP 
statistical analysis. We observed that subtype A samples were enriched for ‘activated 
stroma’ signature (>90% vs. ≈50% in other subtypes, p = 0.03) (Figure 3D), a signature 
associated with shorter survival (p = 0.030) (Figure 3E). Interestingly, we identified a 
favourable profile of subtype C over other subtypes within ‘activated stroma’ tumours (p = 
0.02) (Figure 3F) and the ‘normal stroma’ group (supplementary material, Figure S3D).  
We next sought to explore the associations with known transcriptomic tumour 
subtypes (those of Collisson et al. [11] and Bailey et al. [12], Figure 3G-H). Similarly to 
Moffitt/pCAFassigner subtype association, poor prognostic (QM‐PDA/squamous) tumour 
subtypes were more frequently observed in samples with dominant subtype A CAFs (50% vs. 
18.5%, p = 0.03 and p = 0.06, respectively), suggesting a specific tumour-stromal interaction 
associated with adverse outcome. 
CAF subtypes display specific molecular and functional features 
Since pCAF subtype A displayed specific spatial expression pattern (Figure 2D) and 
prognostic features (Figure 3A-D, G-H), we next compared the primary CAF cultures 
belonging to subtype A vs. other subtypes for molecular and functional features, using the 
well-characterised immortalised stellate cell line (PS1) derived from normal pancreas and 
MRC5 human embryonic lung fibroblasts as standard references [26]. 
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Subtype A CAF cultures displayed low expression of the activation marker αSMA (p = 
0.048) and low vimentin expression (p = 0.031) by western blot, compared to other pCAF 
subtypes (Figure 4A-C and supplementary material, Figure S4A, B). αSMA and vimentin 
high/low status were also validated by immunofluorescence (supplementary material, Figure 
S4D, E). In contrast, PDGFRα was not differentially expressed between these two CAF groups 
(p = 0.92), which confirmed its status as a pan-CAF marker (Figure 4A, D and supplementary 
material, Figure S4C) [27]. In addition, subtype A pCAF cultures displayed a trend for higher 
proliferative activity assessed by MTS assay (p = 0.15) (Figure 4E and supplementary 
material, Figure 4F, G). In contrast, no difference was observed in terms of reversion to 
quiescence upon all-trans retinoic acid (ATRA) treatment between the two groups (p = 0.87) 
(Figure 4F-H and supplementary material, Figure S4H). Similarly, no difference was observed 
in terms of cell size, both subtype A and other subtype CAF culture cells being significantly 
larger than non-tumoral stellate cells (p < 0.001) (supplementary material, Figure S4I). These 
phenotypic features are summarised in Figure 4I. 
CAF subtypes differentially affect cancer cells 
With this phenotypic knowledge, and bearing in mind the paucity of primary CAFs 
and their associated inherent propagation limitations, we compared the functional impact of 
pCAF subtype A vs. other subtypes on cancer cells, in the well-validated pancreatic mini-
organotypic model [28], using PS1 cell line as reference standard and cancer cell (MIAPaCa-2 
or AsPC-1) monocultures without CAF/PSC as negative control (Figure 5A). Co-cultures of 
MIAPaCa-2 with primary CAF cultures resulted in increased cancer cell proliferation in 
comparison to co-culture with non-tumoral PSCs (PS1), as assessed by mean cell layer 
thickness at day 4 (p < 0.0001), and increased cancer cell invasion at day 12 (p = 0.024) 
(Figure 5B-D and supplementary material, Figure S5A). These results with the MIAPaCa-2 
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cancer cell line were validated in co-cultures with the AsPC-1 cell line (supplementary 
material, Figure S5B, C). Composition of CAF cultures in terms of predominant subtype A vs. 
other subtypes translated into differential functional effects on cancer cells. Mini-
organotypic co-cultures with CAF cultures of other subtypes induced more cancer cell 
proliferation (cell layer thickness) than subtype A co-cultures (p = 0.028) (Figure 5B, C). 
Consistently, Ki67 expression by IHC in cancer cells (ratio of Ki67-positive / total nuclei in 
PDGFRα-negative cells, supplementary material, Figure S5D) was increased in mini-
organotypic co-cultures with other pCAF subtypes (p = 0.001) (Figure 5E). This finding 
demonstrated that the increase in cell layer thickness with other pCAF subtypes was the 
direct consequence of cancer cell proliferation induction. Cell layer thickness and Ki67-based 
proliferation were correlated (p < 0.0001), allowing the use of cell layer thickness as a 
surrogate for Ki67-based proliferation assessment in following experiments (Figure 5F). 
Finally, non-subtype A CAFs were associated with cancer cell protection against gemcitabine 
in mini-organotypic co-cultures with MIAPaCa-2 (p < 0.0001) (Figure 5G and supplementary 
material, Figure S5E) [3]. Taken together, these data suggest that pCAF subtype A CAFs may 
be associated with a less pro-tumoral (less pro-proliferative and chemoprotective to cancer 
cells) profile than other, non-subtype A CAFs. 
CAF subtypes reflect dynamic PSC-CAF evolution  
We designed a ‘cancer-education’ experiment to explore the tumour-stroma interaction. We 
exposed non-tumoral PSCs (PS1) to conditioned media (CM) from cancer cell lines (MIAPaCa-
2 and AsPC-1) for two months in standardised culture conditions (supplementary material, 
Figure S6A). Following the education process, PSC cultures (i) became enriched in large cells 
with a clear nucleus (p = 0.006) (Figure 6A and supplementary material, Figure S6B), and (ii) 
lost their sensitivity to ATRA (p = 0.03) (Figure 6B and supplementary material, Figure S6C), 
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consistent with primary CAF features, suggesting a potential “CAF-like” phenotypic switch. In 
addition, educated PS1 displayed decreased αSMA expression (assessed by western blot, p = 
0.07) (Figure 6C and supplementary material, Figure S6D). Moreover, these features were 
maintained after a one-month wash-out period in standard medium (‘reversion’ samples). 
Overall, no significant phenotypic difference was observed between MIAPaCa‐2‐ and AsPC‐1‐
education of PS1 cells in vitro. We next compared gene expression in educated vs. parental 
PS1, using Nanostring analysis. Remarkably, out of the 101 genes that appeared significantly 
modulated by education, 60 had been previously identified in the pCAFassigner extended 
gene list (Figure 6D). Consistent with previous phenotypic findings, there was a large overlap 
in up/downregulated genes between MIAPaCa‐2‐ and AsPC‐1‐educated PS1 (Fisher’s exact 
test, p < 0.0001), with only 8/60 (13.3%) genes showing opposite regulation (supplementary 
material, Table S6). The 31 common genes upregulated in both MiAPaCa‐2‐educated and 
AsPC‐1‐educated PS1 (log10(fold change) > 0) were involved in ECM regulation (including 
matrix metalloproteinases), as well as immune pathways (including lymphocyte and 
granulocyte pathways), which was evocative of subtype C signature (supplementary 
material, Table S7). Conversely, the 21 identified common downregulated genes (log(fold 
change) < 0) were involved in matrisome and core matrisome, suggesting a switch in the 
balance between ECM production and degradation (supplementary material, Table S7). In 
mini-organotypic models with PS1 cells seeded within the gel, there was a remarkable 
reduction in gel thickness with educated PS1 compared to parental PS1, thus functionally 
validating the RNA-signatures associated with ‘cancer-education’ experiments (Figure 6E).  
By analysing the 60 genes into pCAF subtypes, we observed that they were 
differentially modulated by education (p < 0.0001 and p = 0.035 in MIAPaCa‐2‐ and AsPC‐1‐
educated PS1, respectively, when considering fold change values, and p = 0.10 and p = 0.16, 
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respectively, when considering log(fold change) values) (Figure 6F, G). The ratio of numbers 
of upregulated genes over total genes per subtype showed an increase in both subtypes B 
and C (ratio > 0.5), showing that transcriptomic signatures associated with these two CAF 
subtypes can be induced by exposure to soluble factors (supplementary material, Figure S6E, 
F). 
Immunofluorescence co-staining experiments with POSTN, MYH11, and PDPN on 
parental and educated PS1 (supplementary material, Figure S6G) revealed that while POSTN 
was diffusely expressed in PS1 across all the conditions, MIAPaCa-2 and AsPC-1-educated 
PS1 showed a homogeneous decrease in POSTN (subtype A-related) staining intensity and 
increase in MYH11-positive (subtype B-related) and PDPN-positive (subtype C-related) cells, 
with presence of double- and triple-positive hybrid cells, suggesting for the first time (to our 
knowledge) an in vitro read-out for cancer-educated fibroblasts. This switch in pCAFassigner 
marker expression in educated PS1 might represent a transition from subtype A-like 
phenotype toward subtype B/C. 
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DISCUSSION 
Using molecular and functional analyses on human PDAC-derived CAF primary 
cultures, as well as in silico and IHC analyses, we propose a classification of pancreatic CAFs 
(pCAFassigner), demonstrating inter- and intra-tumoral heterogeneity of CAFs in human 
PDAC. We identified at least four distinct pCAF subtypes, associated with specific phenotypic 
features and prognostic impact. Periostin (a subtype A biomarker) is strongly expressed at 
the invasive front in human PDAC samples [24] and has been linked to tumour capsule 
formation at the primary tumour site [29] and metastatic niche preparation at distant sites 
[30,31]. Furthermore, high POSTN protein expression was associated with aggressive 
molecular tumour features and shorter survival. Lastly, our in vitro functional data 
demonstrates that subtype A is less pro-tumoral, suggesting that this subtype may be more 
a consequence than a cause of aggressive PDAC behaviour. 
Myosin-11, a smooth muscle myosin belonging to the myosin heavy chain family, was 
selected as subtype B marker. Interestingly, Lambrechts et al. [16] identified a cluster 
(fibroblast 2) expressing αSMA and MYH11, displaying myogenic properties, similar to pCAF 
subtype B. Podoplanin-positive CAFs have been previously associated with poor prognosis in 
several cancers [32-37]. In PDAC, PDPN expression was associated with larger tumours [36], 
and was relevant for prognosis only in large tumours with lymph node metastasis [37], which 
themselves are adverse prognostic features. Subtype C CAFs (where PDPN is one of the top 
genes) appear to have an immunogenic profile, which, in part, may explain the good 
prognosis observed in the ICGC and IHC analysis. Some studies in other cancer types support 
this hypothesis, showing a positive association between PDPN-positive CAFs and lymphocyte 
and macrophage infiltration [38-40], as well as tumours with a high mutation burden 
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[41,42], suggesting that PDPN expression may be an indicator of immunogenic tumours. We 
summarise these findings in Figure 6H. 
Moreover, our cancer education experiment showed that several pCAF subtypes can 
be induced from PSCs in vitro, and suggested that CAF subtypes might be dynamic, 
fluctuating states for CAFs which may be modulated by signals from cancer cells, but also 
possibly by other stromal cells, such as immune cells. An alternative hypothesis is that CAF 
sub-populations may emerge from distinct cellular origins [43,44]. 
This classification was achieved through international collaboration. We believe that 
it merits independent, prospective validation of the proposed inter- and intra-tumoral 
heterogeneity, dynamics and prognostic impact in larger, independent cohorts, and also the 
evaluation of its relevance to other pancreatic diseases, such as chronic pancreatitis, as well 
as functional ascertainment in murine models of PDAC. Single cell analysis [16,45] may 
further advance the understanding of CAF heterogeneity that is currently suggested by our 
bulk culture analyses, in which there is a mixture of intra-tumour heterogeneous CAFs. In 
addition, this technique may reveal additional subtypes that cannot be cultured or 
expanded. 
So far, studies of CAF sub-populations in PDAC and other cancers have been mainly 
descriptive and relied on previously reported stromal markers [6,7,46-48]. Although IHC 
analyses, using multiple CAF markers, confirmed the positivity of most PDAC tumour 
samples for these proteins, these authors did not demonstrate the simultaneous existence 
of spatially distinct CAF sub-populations (i.e. intra-tumour heterogeneity) and did not 
explore their functions [46]. Ikenaga et al. [47] showed the presence of two sub-populations 
of CAFs in human PDAC stroma (CD10-positive and CD10-negative), with the former having a 
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more pro-tumoral role. Su et al. [49] recently confirmed this finding in breast and lung 
cancers, and demonstrated that a subset of CD10-positive CAFs (CD10+GPR77+) promote 
cancer formation and chemoresistance by sustaining cancer stemness. In contrast, we used 
a “without a priori” approach, based on the transcriptomic profile of primary cultures to 
build an assignation, and described distinct phenotypic profiles of CAF sub-populations. 
Öhlund et al. [7] proposed a binary, simultaneous existence of αSMA-positive 
(“myofibroblastic CAFs”), and αSMA-negative/IL6-positive (“inflammatory CAFs”) sub-
populations in spatially distinct zones in PDAC tissue, mainly through murine data. Kalluri et 
al. [17] also presented preliminary data for a binary classification based on FAP and αSMA 
expression. Using genetic ablation of FAP-positive or αSMA-positive CAF populations in 
mouse models, they identified FAP-positive CAFs as pro-tumoral vs. αSMA-positive CAFs as 
anti-tumoral. Our results indicate that CAF heterogeneity in PDAC is more complex than a 
“αSMA-positive vs. negative” dichotomy. 
Intriguingly, it has been suggested that CAFs grown ex vivo as monolayer cultures 
should converge towards a singular myofibroblastic, αSMA-positive profile [7]. This is 
refuted by our observation that both αSMA-positive and -negative CAFs can be successfully 
grown in monolayer culture conditions. In addition, it has been reported that cancer cells, in 
vitro [7] and in vivo [50], could quickly recruit and subvert non-tumoral PSCs to a phenotype 
that aids cancer cell growth and metastasis. We showed that, beyond transitory activation, a 
stable “CAF-like” phenotype, including loss of capacity to revert to quiescence, can be 
induced by prolonged exposure of non-tumoral PSCs to CM from cancer cell lines in vitro 
(cancer-education and reversibility experiments), providing new insight into PSC/CAF 
plasticity [6,50]. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
Our demonstration that PDAC CAFs are not a homogenous entity may partially 
account for inconsistencies in preclinical results and the failure of some stroma-targeting 
agents [8-10]. Caution is thus indicated when interpreting results from experimental models 
using immortalized CAFs or primary cultures. Indeed, we showed that pCAFs display 
molecular and functional diversity, like cancer cells and other immune cells, and they should 
be carefully characterized. We postulate that our molecular classification and derived assays 
will allow better understanding of PDAC tumour-stroma interactions. 
Deciphering PDAC heterogeneity is a major goal to improve therapeutic strategies 
and patient management. As CAFs play a crucial role as microenvironment orchestrators, 
particularly by producing ECM and interacting with cancer and immune cells [6,51], they are 
involved in PDAC therapeutic resistance. Our results provide the first evidence for CAF-based 
patient prognostic stratification in PDAC. In breast cancer, CAF subtypes have already been 
proposed as predictive markers of response to immune therapy [52]. It is therefore 
envisaged that therapeutic advantage may be gained by specifically targeting deleterious, 
immunosuppressive CAF sub-populations [53]. 
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FIGURE LEGENDS 
Figure 1. Pancreatic ductal adenocarcinoma (PDAC) cancer-associated fibroblast (CAF) 
classification (pCAFassigner). (A) Cophenetic correlation plot for k = 2 to k = 5 classes after 
non-negative matrix factorisation (NMF) for transcriptome of the 16 patient-derived CAF 
primary cultures. The maximum cophenetic coefficient value was reached for k = 4 classes 
(>0.99). (B) Consensus matrix clustering after NMF for transcriptome of the 16 patient-
derived CAF primary cultures for k = 4 classes. (C) Heatmap with hierarchical clustering for 
15 selected metagenes that were found most discriminating between patient-derived CAF 
primary cultures (short pCAFassigner). Significantly higher expression is shown in red and 
lower expression in green. (D) Heatmap showing 248 metagenes (extended pCAFassigner) 
between CAF subtypes, based on prediction for microarrays (PAM)-derived centroids. 
Significantly higher expression is shown in red and lower expression in blue. (E) Gene 
expression pathways using mSigDB database [54]. We selected genes from the extended 
pCAFassigner with a PAM centroid value > 0.10 in each CAF subtype. Top-10 pathways for 
each CAF subtype are displayed. Significantly lower q-value (i.e. false discovery rate [FDR]-
adjusted p-value) is shown in red and higher q-value in yellow/white. 
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Figure 2. Molecular markers for pancreatic ductal adenocarcinoma (PDAC) cancer-associated 
fibroblasts (CAF). (A) Heatmap of CAF culture (n = 16) probability of belonging to 
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pCAFassigner subtypes. Significantly higher probability is shown in red and lower probability 
in blue. (B) Correlation of pCAFassigner subtype PAM centroids with Lambrechts et al. [16] 
fibroblast subtype gene expression. Only positive correlations were shown. (C) Prediction for 
microarrays (PAM) centroids (expression levels) of POSTN, MYH11, and PDPN according to 
pCAFassigner subtypes. (D) H&E stain and immunohistochemical staining for periostin 
(POSTN), myosin-11 (MYH11), podoplanin (PDPN), α-smooth muscle actin (αSMA), and 
platelet-derived growth factor receptor α (PDGFRα) on serial sections from a resected PDAC 
sample. Scale bars: 100 μm. (E) Representative pictures of IHC staining for periostin (POSTN), 
myosin-11 (MYH11), and podoplanin (PDPN) in human PDAC samples, showing spatial 
pattern at the invasive margin and in the juxta-tumoral stroma and pan-stroma. Scale bar: 
100 μm. (F) Immunofluorescence co-staining of POSTN (green), MYH11 (red or green), PDPN 
(red), and DAPI (blue) on PSC25 (subtype A), PSC48 (mixed, subtype A dominant > B) and 
PSC11 (subtype C) (merged images). Percentages of positive cells for each marker are 
displayed. Scale bar: 100 μm. 
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Figure 3. Prognostic impact of pancreatic ductal adenocarcinoma (PDAC) cancer-associated 
fibroblast (CAF) subtypes. (A) Kaplan-Meier curves for overall survival (OS) in the 
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International Cancer Genome Consortium (ICGC) dataset (n = 70 PDAC samples with RNAseq 
data from bulk tumour tissue). Subtype A is displayed in red, B in orange, C in green, and D in 
blue. Log-rank tests, overall: p = 0.02; subtype C vs. others: p = 0.004; subtype D vs. others: p 
= 0.03; other comparisons: N.S. (B) Kaplan-Meier curves for OS according to periostin 
(POSTN) expression level by IHC (n = 49). High POSTN expression was defined as moderate or 
strong staining in >50% of stromal surface. Median OS: 29.8 months vs. 46.2 months, in 
POSTNhigh vs. POSTNlow group, respectively. Log-rank test, p = 0.005. (C) Kaplan-Meier curves 
for OS according to combined POSTN, myosin-11 (MYH11), and podoplanin (PDPN) 
expression level by IHC (n = 49). High POSTN expression was defined as moderate or strong 
staining in >50% of stromal surface. High MYH11 and PDPN expressions were defined as the 
presence of strong stromal staining. In case of simultaneous high expression of MYH11 and 
PDPN, the tumour was classified according to the most abundant sub-population. Median OS 
in POSTNhigh/MYH11low/PDPNlow (red): 25.7 months, MYH11high/POSTNlow or 
MYH11high/POSTNhigh (orange): 30.9 months, PDPNhigh/POSTNlow or PDPNhigh/POSTNhigh (green): 
49.6 months, triple negative (POSTNlow/MYH11low/PDPNlow, blue): undefined. Log-rank test for 
trend, p = 0.01. (D) Association between pCAFassigner subtypes and Moffitt et al. stroma 
subtypes in the ICGC dataset (n = 70) as assessed by nearest template prediction (NTP) 
analysis. Chi-square test, p = 0.03. (E) Kaplan-Meier curves for OS according to Moffitt et al. 
stroma subtypes in the ICGC dataset (n = 70). Median OS: 14.1 months vs. 35.8 months in 
activated vs. normal stroma, respectively. Log-rank test, p = 0.03. (F) Kaplan-Meier curves for 
OS according to CAF subtypes in the Moffitt et al. activated stroma group from the ICGC 
dataset (n = 44). Log-rank test, p = 0.02. Median OS in subtype A: 16.6 months, subtype B: 
19.8 months, subtype C: 20.3 months, and subtype D: 8.6 months. (G) Association between 
pCAFassigner subtypes and Collisson et al. [11] tumour subtypes in the ICGC dataset (n = 70) 
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as assessed by NTP analysis. Chi-square test, p = 0.12 (overall), p = 0.03 (subtype A vs. 
others). (H) Association between pCAFassigner subtypes and Bailey et al. [12] tumour 
subtypes in the ICGC dataset (n = 70) as assessed by NTP analysis. Chi-square test, p = 0.24 
(overall), p = 0.06 (subtype A vs. others). 
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Figure 4. Phenotypic features of pancreatic ductal adenocarcinoma (PDAC) cancer-
associated fibroblast (CAF) subtypes. (A) α-smooth muscle actin (αSMA), vimentin, platelet-
derived growth factor receptor α (PDGFRα), and β-actin (actin) expression in CAF primary 
cultures (n = 16) and PS1 and MRC5 (human embryonic lung fibroblast) cell lines (used as 
controls) by western blot. Subtype A CAFs are displayed in red and other subtypes in grey. 
(B) Quantification of αSMA expression normalized to β-actin (actin) using ImageJ®, according 
to pCAFassigner subtype (n = 16). αSMA mean expression normalized to PS1: 15.4 ± 7.2 in 
subtype A vs. 24.2 ± 8.5 in other subtypes, unpaired t-test with Welch’s correction, p = 
0.048. (C) Quantification of vimentin expression normalized to β-actin (actin) using ImageJ®, 
according to pCAFassigner subtype (n = 16). Vimentin mean expression normalized to PS1: 
0.49 ± 0.21 in subtype A vs. 0.78 ± 0.27 in other subtypes, unpaired t-test with Welch’s 
correction, p = 0.031. (D) Quantification of PDGFRα expression normalized to β-actin (actin) 
using ImageJ®, according to pCAFassigner subtype (n=16). PDGFRα mean expression 
normalized to PS1: 51.2 ± 30.4 in subtype A vs. 49.6 ± 35.0 in other subtypes, unpaired t-test 
with Welch’s correction, p = 0.92. (E) Area under the proliferation curve (AUC) assessed by 
MTS assay in CAF primary cultures, according to pCAFassigner subtype (n = 16). Mean AUC 
normalized to PS1: 0.55 ± 0.23 in subtype A vs. 0.32 ± 0.34 in other subtypes, unpaired t-test 
with Welch’s correction, p = 0.15. (F) Ratio of lipid-droplet-positive (quiescent) cells over 
total cells, assessed by Oil Red O staining, in all-trans retinoic acid (ATRA)-treated CAF 
primary cultures (1 μM daily, for 5-7 days, until confluency; n = 16). Mean ratio: 0.068 ± 0.10 
in subtype A vs. 0.076 ± 0.087 in other subtypes, unpaired t-test with Welch’s correction, p = 
0.87. (G, H) Representative images of ATRA-responsive (positive) cells (G) and ATRA-non-
responsive (negative) cells (H) after Oil Red O staining. (I) Heatmap summarising primary CAF 
culture (n = 16) features in terms of αSMA (αSMA/actin ratio by western blot), vimentin 
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(vimentin/actin ratio by western blot) expression, proliferation (AUC of MTS curve), and 
ATRA response (lipid-droplet-positive cells/total cells ratio). All values were normalised to 
PS1 as a reference. Significantly higher values are shown in red and lower values in green. 
 
Figure 5. Influence of cancer-associated fibroblast (CAF) subtypes on cancer cells. 
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(A) Overview of the mini-organotypic experimental system and timelines. (See 
supplementary material, Supplementary Methods, for detailed description.) (B) 
Representative images of H&E-stained sections of mini-organotypics after 4 days (D4), with 
MIAPaCa-2 cells alone (top left), or in co-culture with PS1 (top right), subtype-A CAFs 
(bottom left) or other-subtype CAFs (bottom right). Black vertical lines highlight the cell layer 
thickness. Scale bar: 50 μm. (C) Cell proliferation at D4 assessed by the cell layer thickness, 
measured at two representative points per field in an average of 3 fields with 10 × 
magnification on H&E-stained slides (one mean value per gel). Mean cell layer thickness 
normalized to MIAPaCa-2 alone: 1.00 ± 0.06 in MIAPaCa-2 alone (triplicate), 3.41 ± 0.74 in 
MIAPaCa-2/PS1 co-culture (triplicate), 7.93 ± 1.16 in MIAPaCa-2/subtype A CAF co-culture 
(n=2 distinct CAF cultures), and 9.39 ± 0.27 in MIAPaCa-2/other-subtype CAF co-culture (n = 
2 distinct CAF cultures), Kruskal-Wallis: p < 0.0001. Dunn’s multiple comparisons: MIAPaCa-2 
alone vs. MIAPaCa-2/subtype A: p < 0.01, MIAPaCa-2 alone vs. MIAPaCa-2/other subtypes: p 
< 0.001, other comparisons: N.S. MIAPaCa-2/subtype A vs. MIAPaCa-2/other subtype 
comparison, unpaired t-test with Welch’s correction: p = 0.028. MIAPaCa-2/PS1 vs. 
MIAPaCa-2/subtype A and MIAPaCa-2/PS1 vs. MIAPaCa-2/other subtype comparison, 
unpaired t-test with Welch’s correction: p < 0.001. (D) Representative pictures of H&E-
stained sections for cell invasion at D12 in MIAPaCa-2/PS1 co-cultures, MIAPaCa-2/subtype-
A CAF and MIAPaCa-2/other-subtype CAF co-cultures (n = 1 primary CAF culture per 
subtype). MIAPaCa-2 alone: no invasion. Arrows point at invading cells. Scale bar: 50 μm. (E) 
Cell proliferation at D4 assessed by the ratio of Ki67-positive nuclei over the total number of 
nuclei in cancer cells (PDGFRα-negative). Mean ratio: 0.60 ± 0.05 in MIAPaCa-2 alone 
(triplicate), 0.67 ± 0.05 in MIAPaCa-2/PS1 co-culture (triplicate), 0.74 ± 0.04 in MIAPaCa-
2/subtype-A CAF co-culture (n = 2 distinct CAF cultures), and 0.91 ± 0.05, in MIAPaCa-
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2/other-subtype CAF co-culture (n = 2 distinct CAF cultures), Kruskal-Wallis: p = 0.0001. 
Dunn’s multiple comparisons: MIAPaCa-2 alone vs. MIAPaCa-2/other subtypes: p < 0.01, 
other comparisons: NS. MIAPaCa-2/subtype A vs. MIAPaCa-2/other subtype comparison, 
unpaired t-test with Welch’s correction: p = 0.001. MIAPaCa-2/PS1 vs. MIAPaCa-2/subtype A 
and MIAPaCa-2/PS1 vs. MIAPaCa-2/other subtype comparison, unpaired t-test with Welch’s 
correction: p = 0.13 and p = 0.002, respectively. (F) Correlation plot between cell layer 
thickness and Ki67-based proliferation. MIAPaCa-2 monocultures are displayed in black, 
MIAPaCa-2/PS1 co-cultures in blue, MIAPaCa-2/subtype-A CAF co-cultures in red, and 
MIAPaCa-2/other-subtype CAF co-cultures in grey.  Spearman r = 0.9265, p < 0.0001. (G) Cell 
proliferation at D4 assessed by the cell layer thickness in control or gemcitabine-treated 
(concentration: 100 nM = IC50 of MIAPaCa-2 alone) mini-organotypics, normalized to control 
in each group (triplicate for PS1 co-culture and n=2 distinct CAF cultures per subtype for 
primary cultures). One-way ANOVA with Sidak’s multiple comparisons, mean difference 
gemcitabine-treated vs. control in MIAPaCa-2/other-subtype CAF co-cultures: 0.26 [0.004-
0.51]; in MIAPaCa-2/subtype-A CAF co-cultures: 0.58 [0.41-0.74], p ≤ 0.01; in MIAPaCa-
2/PS1: 0.69 [0.55-0.84], p ≤ 0.0001. 
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Figure 6. Pancreatic stellate cell (PSC)- cancer-associated fibroblasts (CAF) dynamics. (A) 
Ratio of large cells over total cell number in parental PS1, following two-month education 
(‘Educated’), and after one-month wash-out period in normal medium (reversion, ‘Rev’). 
Mean ratio in parental PS1 vs. educated PS1 (duplicate): 0.050 ± 0.016 vs. 0.099 ± 0.026, 
unpaired t-test with Welch’s correction, p = 0.006. (B) Ratio of lipid-droplet-positive 
(quiescent) cells over total cell number in parental PS1 upon all-trans retinoic acid (ATRA) 
treatment (1 μM daily, for 5 days), following two-month education, and after one-month 
wash-out period in normal medium (Rev). Mean ratio in parental PS1 vs. educated PS1 
(duplicate): 0.11 ± 0.04 vs. 0.01± 0.01, unpaired t-test with Welch’s correction, p = 0.006. (C) 
Quantification of α-smooth muscle actin (αSMA) expression normalized to β-actin (actin) 
using ImageJ®, in parental PS1, following two-month education with MIAPaCa-2 or AsPC-1 
CM, and after one-month wash-out period in standard medium (Rev). Mean expression in 
parental PS1 vs. educated PS1 (duplicate): 0.89 ± 0.16 vs. 0.47± 0.21, unpaired t-test with 
Welch’s correction, p = 0.07. (D) Venn diagram showing the overlap (n = 60 genes) between 
pCAFassigner metagenes (n = 248) and education-modulated genes (n = 101, variance < 0.25 
in parental PS1). (E) Representative pictures of H&E-stained slides in mini-organotypics with 
PS1 embedded in the gel in parental PS1, MIAPaCa-2-educated PS1, and AsPC-1-educated 
PS1. Scale bar: 50 μm. (F) Modulation (log10(fold change)) of CAF subtype-specific genes in 
MIAPaCa-2-educated PS1 vs. parental PS1. One-way ANOVA: p = 0.10. (G) Modulation 
(log(fold change)) of CAF-subtype specific genes in AsPC-1-educated PS1 vs. parental PS1. 
One-way ANOVA: p = 0.16. (H) Pancreatic CAF heterogeneity model. CAF subtypes were 
associated with distinct molecular and functional features (ECM- and immune-related 
signatures, intra-tumoral spatial pattern of expression, vimentin and αSMA expression, 
proliferation rate, tumour-promoting and chemoprotective capabilities) and had a 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
prognostic impact. Periostin (POSTN), myosin-11 (MYH11), and podoplanin (PDPN) were 
identified as subtype A, B, and C markers, respectively. 
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